Skip to main content

Volume 3 Supplement 1

Abstracts of the Breast Cancer Immunotherapy Symposium (BRECIS): Sidra Symposia Series

Foxp3 expression in breast cancer patient from Qatar: survival analysis

In breast cancer, the presence of Foxp3 (Tregs) [1] within the tumor milieu has been a matter of debate. Some studies have determined that infiltration of Tregs was associated with poor survival, while others revealed no impact on survival, however this depends on their type, type of cells expressing Foxp3 and the density of the Tregs population [2].

The goal of our study was to quantify Foxp3 in breast cancer patients from Qatar and correlate with their survival.

Methodology

Expression of FoxP3 was studied in 132 FFPE samples with known clinico-pathological data by immunohistochemistry technique and quantified by modified H-score system by pathologist. Results were analyzed via SPSS.

Results

Analysis was carried for 132 patients. Age at time of diagnosis was 49 ±10.4 years. 76.2% of the patients showed positive expression of FoxP3. FoxP3 expression was not correlated with patient age or hormone receptors. Expression of Foxp3 positively correlate with better patient survival when compared to negative expression (94.1, 95% CI 85.6 - 102.6 versus 83.6, 95% CI 71.8 - 95.5, p 0.60).

Conclusion

FoxP3 is expressed on lymphocytes that are present in the tumor microenvironment regardless of breast cancer subtypes. Foxp3 is correlated with better survival.

References

  1. 1.

    Mackay C.R.: Dual personality of memory T cells. Nature. 1999, 401 (6754): 659-660. 10.1038/44309.

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Mahmoud S.M., Paish E.C., Powe D.G., Macmillan R.D., Lee A.H., Ellis I.O., Green A.R.: An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Research and Treatment. 2011b, 127 (1): 99-108. 10.1007/s10549-010-0987-8.

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Shahinaz Bedri.

Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.

The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mohamed, M.G., Sarwath, H., Alqahtani, S. et al. Foxp3 expression in breast cancer patient from Qatar: survival analysis. j. immunotherapy cancer 3, O2 (2015). https://doi.org/10.1186/2051-1426-3-S1-O2

Download citation

Keywords

  • Breast Cancer
  • Breast Cancer Patient
  • Survival Analysis
  • Hormone Receptor
  • Tumor Microenvironment